CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC)
AssigneeTonix Pharmaceuticals Holding Corp
InventorSeth Lederman
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Claims32
A method for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
(canceled)
(canceled)
(canceled)
-16. (canceled)
(canceled)
20-21. (canceled)
-24. (canceled)
-35. (canceled)
-39. (canceled)
-42. (canceled)
-53. (canceled)
(canceled)
Dependencies are inferred from the claim text.